Literature DB >> 20647710

[Correlation between clinicopathological factors and enzymatic activity of orotate phosphoribosyl transferase (OPRT), dihydropyrimidine dehydrogenase (DPD) in esophageal cancer].

Masashi Takemura1, Kayo Yoshida, Keiichirou Morimura, Harushi Osugi, Shigeru Lee, Satoru Kishida.   

Abstract

We investigated the relationship between orotate phosphoribosyl transferase (OPRT), dihydropyrimidine dehydrogenase (DPD) and clinicopathological characteristics in 48 patients with esophageal cancer. DPD activity resulted in no significant differences between cancer tissue and normal tissue, and no relationship with clinicopathological factors. OPRT activity was significantly increased in cancer tissue; its activity was significantly lower in patients with lymph node metastasis and lymph vessel invasion, and significantly higher in Stage I and II than in Stage III and IV. The OPRT/DPD ratio has a relation to cancer staging and survival rate. These results suggested that OPRT levels were related to the clinic pathological characteristics and survival of esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647710

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  A case of long-term survival after pulmonary resection for metachronous pulmonary metastasis of basaloid squamous cell carcinoma of the esophagus.

Authors:  Masashi Takemura; Kayo Yoshida; Yushi Fujiwara; Katsunobu Sakurai; Mamiko Takii
Journal:  Int J Surg Case Rep       Date:  2012-06-01

2.  Metachronous pulmonary metastasis after radical esophagectomy for esophageal cancer: prognosis and outcome.

Authors:  Masashi Takemura; Katsunobu Sakurai; Mamiko Takii; Kayo Yoshida
Journal:  J Cardiothorac Surg       Date:  2012-10-02       Impact factor: 1.637

3.  Comment on "influence of orotate phosphoribosyl transferase levels on tumor prognosis and response to chemotherapy".

Authors:  Shailendra Kapoor
Journal:  J Oncol       Date:  2012-10-03       Impact factor: 4.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.